Nanozyme compositions and methods of treatment
View Patent ↗In one aspect, compositions and therapeutic use thereof are provided that can inhibit α-synuclein cell-to-cell transmission. In embodiment, methods are provided to treat a mammal such as a human that is suffering from or susceptible to an α-synucleinopathy that include administering to the mammal an effective amount of one or more metal nanozymes.
1 . A method of treating a mammal suffering from an α-synucleinopathy comprising administering to the mammal an effective amount of one or more metal nanozymes.
2 . The method of claim 1 wherein the one or more nanozymes or Pt agent is a nanoalloy.
3 . The method of claim 1 wherein the mammal or subject is suffering or susceptible to Parkinson's disease.
4 . The method of claim 1 wherein the mammal or subject is suffering from dementia with Lewy bodies.
5 . The method of claim 1 wherein the mammal or subject is suffering from Parkinson's disease with dementia, multiple system atrophy, and 1/3 of Alzheimer's disease with α-synucleinopathy.
6 . The method of claim 1 wherein the mammal or subject is suffering from or susceptible to Alzheimer's disease or a trinucleotide repeat expansion disorder.
7 . The method of claim 1 wherein the mammal or subject is suffering from Huntington's disease, spinal or bulbar muscular atrophy, spinocerebellar ataxia type 1, dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, spinocerebellar ataxia type 2, spinocerebellar ataxia type 6, or spinocerebellar ataxia type 7.
8 . The method of claim 1 wherein a-synuclein aggregation is inhibited in the subject by administration of the nanozyme or Pt agent.
9 . The method of claim 1 wherein neuronal cells are treated by the one or more nanozymes or Pt agents.
10 . The method of claim 1 wherein the one or more metal nanozymes comprise one or more Pt agents.
11 . The method of claim 10 wherein the one or more Pt agents comprises PtCu, PtNi, PtAu, PtAg, PtFe and/or PtSn.
12 . The method of claim 10 wherein the one or more Pt agents comprises PtCu.
13 . A method for treating or delaying onset of a proteinopathy, comprising: administering to a subject in need thereof an effective amount of one or more metal nanozymes.
14 . A method of treating α-synuclein aggregation in the cells of a subject suffering from an α-synucleinopathy, comprising administering an effective amount of one or more metal nanozymes.
15 . The method of claim 14 wherein the one or more metal nanozymes comprise one or more Pt agents.
16 . The method of claim 15 wherein the one or more Pt agents comprises PtCu, PtNi, PtAu, PtAg, PtFe and/or PtSn.
17 . The method of claim 15 wherein the one or more Pt agents comprises PtCu.
18 . A method of treating a mammal suffering from Parkinson's disease, comprising administering to the mammal an effective amount of one or more metal nanozymes.
19 . The method of claim 18 wherein the one or more metal nanozymes comprise one or more Pt agents.
20 . The method of claim 19 wherein the one or more Pt agents comprises PtCu, PtNi, PtAu, PtAg, PtFe and/or PtSn.